Metabolic Dysfunction-Associated Steatohepatitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Metabolic Dysfunction-Associated Steatohepatitis (US)
The metabolic dysfunction-associated steatohepatitis (MASH) landscape is undergoing a notable shift as new pharmacologic options become available for a condition long managed primarily through lifestyle modification and treatment of comorbidities. The approvals of the THR-β agonist Rezdiffra (resmetirom) and GLP-1 receptor agonist Wegovy (semaglutide) are prompting a reassessment of how these therapies fit within existing treatment pathways focused on managing metabolic comorbidities. The MASH Treatment Algorithm offers insights into the rapidly evolving prescribing patterns and patient management in the U.S. market.
What patient shares do key therapies and brands garner by line of therapy in newly diagnosed MASH patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MASH patients?
- How has resmetirom (Rezdiffra) been integrated into the treatment algorithm, and what is its source of business?
- What percentage of MASH patients receive drug therapy within a year of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within a year of diagnosis?
- What percentage of MASH patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Markets covered: United States
Key drugs: Resmetirom, GLP-1 receptor agonists, SGLT-2 inhibitors, statins
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
